The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to ...
Cardinal Health's analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology rising in adoption and accessibility gains.
Biopharmaceutical company AbbVie plans to spend $380 million building two new manufacturing facilities in North Chicago — a ...
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...
Zacks Investment Research on MSN
Here's why AbbVie (ABBV) is a strong growth stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market.
Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results